Interestingly, the FGFR3::TACC3 fusion is considered an FGFRi predictive biomarker in gliomas (NCT02824133, NCT04424966) and cholangiocarcinoma (NCT03773302) [66]. This evidence concerns the gene FGFR3 and central nervous system cancer.